Medicinal Chemistry Bioorganic & Medicinal Chemistry Letters
Lysine and tyrosine ligandability points to mitochondrial disease targets
- Cross-referencing proteins with chemoproteomically ligandable lysine or tyrosine residues against human genetics shows enrichment for genes behind mitochondrial DNA depletion syndromes.
- SUCLG1 carries a ligandable active-site lysine, a possible handle for covalent inhibition.
- AGK has a ligandable tyrosine that could support an allosteric approach to modulating mitochondrial and immune signaling.
- Offered as a framework for prioritizing genetically validated targets for covalent probes.
A ligandable lysine is not necessarily an inhibitable one. SUCLG1's active-site lysine may sit where a CoA or nucleotide substrate binds, so whether a sulfonyl fluoride or activated-ester probe actually abolishes activity, and spares the heterodimer partner, remains open. For AGK, binding at a tyrosine only becomes an allosteric story once a functional readout backs it.
Paper: Bioorganic & Medicinal Chemistry Letters ↗ Mapping of Ligandable tyrosine and lysine residues in proteins implicated in mitochondrial DNA depletion and therapeutic relevance